Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Experimental | 11 | 2023 | 195 | 3.610 |
Why?
|
| Endothelin-1 | 6 | 2022 | 122 | 1.820 |
Why?
|
| Endothelial Cells | 6 | 2022 | 384 | 1.760 |
Why?
|
| Microvessels | 3 | 2022 | 43 | 1.620 |
Why?
|
| Cognitive Dysfunction | 4 | 2022 | 176 | 1.430 |
Why?
|
| Stroke | 7 | 2023 | 2163 | 1.230 |
Why?
|
| Infarction, Middle Cerebral Artery | 5 | 2023 | 105 | 1.200 |
Why?
|
| Receptor, Endothelin A | 4 | 2022 | 35 | 1.140 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2022 | 22 | 0.850 |
Why?
|
| Vascular System Injuries | 1 | 2022 | 20 | 0.840 |
Why?
|
| Dementia, Vascular | 1 | 2022 | 22 | 0.840 |
Why?
|
| Microglia | 2 | 2021 | 143 | 0.820 |
Why?
|
| Receptors, Opioid, delta | 4 | 2017 | 37 | 0.800 |
Why?
|
| Retinal Ganglion Cells | 5 | 2017 | 72 | 0.770 |
Why?
|
| Diabetes Complications | 2 | 2020 | 249 | 0.760 |
Why?
|
| Endothelium, Vascular | 3 | 2020 | 371 | 0.730 |
Why?
|
| Neuroprotective Agents | 4 | 2021 | 317 | 0.720 |
Why?
|
| Lipopolysaccharides | 2 | 2020 | 455 | 0.690 |
Why?
|
| Receptors, Endothelin | 2 | 2022 | 30 | 0.680 |
Why?
|
| Brain | 7 | 2022 | 2176 | 0.680 |
Why?
|
| Rats, Wistar | 7 | 2022 | 371 | 0.670 |
Why?
|
| Rats | 13 | 2023 | 5300 | 0.650 |
Why?
|
| Disease Models, Animal | 7 | 2023 | 2550 | 0.650 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2018 | 17 | 0.630 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2018 | 114 | 0.590 |
Why?
|
| Brain Ischemia | 2 | 2023 | 665 | 0.560 |
Why?
|
| Ocular Hypertension | 2 | 2013 | 43 | 0.520 |
Why?
|
| Benzamides | 4 | 2017 | 156 | 0.490 |
Why?
|
| Animals | 21 | 2023 | 20881 | 0.480 |
Why?
|
| Piperazines | 4 | 2017 | 206 | 0.480 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 1085 | 0.400 |
Why?
|
| Receptor, Endothelin B | 3 | 2022 | 34 | 0.390 |
Why?
|
| Cell Line | 4 | 2021 | 1752 | 0.330 |
Why?
|
| Cerebrovascular Circulation | 4 | 2022 | 296 | 0.330 |
Why?
|
| Sulfonamides | 2 | 2019 | 141 | 0.300 |
Why?
|
| Glaucoma | 2 | 2017 | 50 | 0.260 |
Why?
|
| Optic Disk | 3 | 2017 | 37 | 0.250 |
Why?
|
| Blood Glucose | 2 | 2020 | 631 | 0.240 |
Why?
|
| Cell Survival | 3 | 2018 | 901 | 0.240 |
Why?
|
| Deferoxamine | 2 | 2022 | 45 | 0.230 |
Why?
|
| Male | 11 | 2022 | 37321 | 0.230 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2013 | 626 | 0.220 |
Why?
|
| Blotting, Western | 6 | 2017 | 954 | 0.220 |
Why?
|
| Diet, High-Fat | 2 | 2020 | 81 | 0.220 |
Why?
|
| Astrocytes | 3 | 2017 | 270 | 0.220 |
Why?
|
| Cerebrum | 1 | 2022 | 20 | 0.210 |
Why?
|
| Bacteroidaceae Infections | 1 | 2022 | 15 | 0.200 |
Why?
|
| Endothelins | 2 | 2022 | 57 | 0.200 |
Why?
|
| Porphyromonas gingivalis | 1 | 2022 | 33 | 0.200 |
Why?
|
| Electroretinography | 4 | 2017 | 122 | 0.200 |
Why?
|
| Cell Line, Transformed | 2 | 2018 | 100 | 0.200 |
Why?
|
| Hyperglycemia | 1 | 2023 | 158 | 0.190 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2021 | 31 | 0.190 |
Why?
|
| Streptozocin | 1 | 2020 | 34 | 0.180 |
Why?
|
| Cell Hypoxia | 1 | 2020 | 92 | 0.170 |
Why?
|
| Culture Media | 1 | 2020 | 155 | 0.170 |
Why?
|
| Rats, Inbred BN | 3 | 2017 | 51 | 0.170 |
Why?
|
| Humans | 11 | 2022 | 68618 | 0.170 |
Why?
|
| Neuroimmunomodulation | 1 | 2019 | 16 | 0.170 |
Why?
|
| Immunohistochemistry | 4 | 2017 | 1174 | 0.170 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2019 | 22 | 0.160 |
Why?
|
| Furans | 1 | 2019 | 27 | 0.160 |
Why?
|
| Female | 9 | 2022 | 38074 | 0.160 |
Why?
|
| Inflammasomes | 1 | 2019 | 39 | 0.160 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 126 | 0.160 |
Why?
|
| Palmitates | 1 | 2018 | 20 | 0.160 |
Why?
|
| Th17 Cells | 1 | 2019 | 116 | 0.160 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 37 | 0.150 |
Why?
|
| Neuroprotection | 1 | 2017 | 28 | 0.150 |
Why?
|
| Necrosis | 1 | 2018 | 239 | 0.150 |
Why?
|
| Retinal Diseases | 1 | 2017 | 40 | 0.150 |
Why?
|
| Mice | 5 | 2021 | 8474 | 0.140 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2018 | 124 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2019 | 295 | 0.140 |
Why?
|
| Sex Factors | 1 | 2020 | 1266 | 0.140 |
Why?
|
| Glucose | 1 | 2018 | 307 | 0.140 |
Why?
|
| Linagliptin | 1 | 2016 | 6 | 0.130 |
Why?
|
| Neurons | 2 | 2019 | 881 | 0.130 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2013 | 134 | 0.130 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2016 | 34 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 331 | 0.130 |
Why?
|
| Intraocular Pressure | 2 | 2013 | 143 | 0.130 |
Why?
|
| Chronic Disease | 3 | 2017 | 1330 | 0.120 |
Why?
|
| Recovery of Function | 1 | 2018 | 506 | 0.120 |
Why?
|
| Retina | 2 | 2014 | 252 | 0.120 |
Why?
|
| Signal Transduction | 3 | 2020 | 2689 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1745 | 0.120 |
Why?
|
| Monophenol Monooxygenase | 1 | 2014 | 8 | 0.120 |
Why?
|
| Inflammation | 1 | 2020 | 1030 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2014 | 135 | 0.110 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 89 | 0.110 |
Why?
|
| Cytoprotection | 1 | 2013 | 39 | 0.110 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2013 | 145 | 0.110 |
Why?
|
| Interferon-gamma | 1 | 2014 | 241 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 362 | 0.110 |
Why?
|
| Nitric Oxide | 1 | 2014 | 382 | 0.100 |
Why?
|
| Morphine | 1 | 2012 | 76 | 0.100 |
Why?
|
| Apoptosis | 1 | 2018 | 1641 | 0.100 |
Why?
|
| Hippocampus | 3 | 2019 | 471 | 0.090 |
Why?
|
| Retinal Degeneration | 1 | 2012 | 75 | 0.090 |
Why?
|
| Ischemia | 1 | 2012 | 229 | 0.090 |
Why?
|
| Analgesics, Opioid | 2 | 2012 | 498 | 0.090 |
Why?
|
| Cells, Cultured | 3 | 2017 | 2673 | 0.070 |
Why?
|
| Optic Nerve | 2 | 2017 | 55 | 0.060 |
Why?
|
| Hemin | 1 | 2022 | 10 | 0.050 |
Why?
|
| Base Composition | 1 | 2022 | 22 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 85 | 0.050 |
Why?
|
| Disease Progression | 2 | 2017 | 1038 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2014 | 1040 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2022 | 99 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2022 | 208 | 0.050 |
Why?
|
| Phylogeny | 1 | 2022 | 197 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2019 | 53 | 0.040 |
Why?
|
| Indenes | 1 | 2019 | 6 | 0.040 |
Why?
|
| Sulfones | 1 | 2019 | 45 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 167 | 0.040 |
Why?
|
| Interleukin-17 | 1 | 2019 | 62 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 234 | 0.040 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2019 | 34 | 0.040 |
Why?
|
| Intestines | 1 | 2019 | 114 | 0.040 |
Why?
|
| Endothelin B Receptor Antagonists | 1 | 2018 | 11 | 0.040 |
Why?
|
| Endothelin A Receptor Antagonists | 1 | 2018 | 22 | 0.040 |
Why?
|
| Neurovascular Coupling | 1 | 2018 | 9 | 0.040 |
Why?
|
| Cell Division | 1 | 2019 | 541 | 0.040 |
Why?
|
| Muscle Development | 1 | 2018 | 31 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 397 | 0.040 |
Why?
|
| Cognition | 1 | 2021 | 513 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2018 | 183 | 0.040 |
Why?
|
| Homeostasis | 1 | 2018 | 291 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2018 | 241 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 317 | 0.030 |
Why?
|
| Stilbamidines | 1 | 2014 | 13 | 0.030 |
Why?
|
| Guanidines | 1 | 2014 | 32 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2014 | 201 | 0.030 |
Why?
|
| Sesquiterpenes, Guaiane | 1 | 2013 | 3 | 0.030 |
Why?
|
| Sesquiterpenes | 1 | 2013 | 41 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 507 | 0.030 |
Why?
|
| Opioid Peptides | 1 | 2012 | 17 | 0.030 |
Why?
|
| Caspases | 1 | 2012 | 194 | 0.030 |
Why?
|
| Receptors, Opioid | 1 | 2012 | 60 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2013 | 432 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 1033 | 0.020 |
Why?
|
| Ligands | 1 | 2012 | 317 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 659 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 244 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 2791 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 3259 | 0.020 |
Why?
|